![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LARP1B |
Gene summary for LARP1B |
![]() |
Gene information | Species | Human | Gene symbol | LARP1B | Gene ID | 55132 |
Gene name | La ribonucleoprotein 1B | |
Gene Alias | LARP2 | |
Cytomap | 4q28.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q659C4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55132 | LARP1B | PTC01 | Human | Thyroid | PTC | 1.02e-12 | 9.86e-02 | 0.1899 |
55132 | LARP1B | PTC03 | Human | Thyroid | PTC | 3.45e-04 | 2.13e-01 | 0.1784 |
55132 | LARP1B | PTC04 | Human | Thyroid | PTC | 2.18e-13 | 3.10e-01 | 0.1927 |
55132 | LARP1B | PTC05 | Human | Thyroid | PTC | 4.12e-15 | 6.39e-01 | 0.2065 |
55132 | LARP1B | PTC06 | Human | Thyroid | PTC | 2.45e-20 | 5.32e-01 | 0.2057 |
55132 | LARP1B | PTC07 | Human | Thyroid | PTC | 4.26e-31 | 5.10e-01 | 0.2044 |
55132 | LARP1B | ATC09 | Human | Thyroid | ATC | 1.74e-05 | 1.30e-01 | 0.2871 |
55132 | LARP1B | ATC12 | Human | Thyroid | ATC | 3.66e-17 | 1.69e-01 | 0.34 |
55132 | LARP1B | ATC13 | Human | Thyroid | ATC | 1.46e-25 | 3.13e-01 | 0.34 |
55132 | LARP1B | ATC1 | Human | Thyroid | ATC | 1.17e-04 | 1.47e-01 | 0.2878 |
55132 | LARP1B | ATC2 | Human | Thyroid | ATC | 3.65e-10 | 4.97e-01 | 0.34 |
55132 | LARP1B | ATC3 | Human | Thyroid | ATC | 4.30e-03 | 1.58e-01 | 0.338 |
55132 | LARP1B | ATC4 | Human | Thyroid | ATC | 2.92e-16 | 2.25e-01 | 0.34 |
55132 | LARP1B | ATC5 | Human | Thyroid | ATC | 1.04e-17 | 3.48e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LARP1B | SNV | Missense_Mutation | c.244C>T | p.His82Tyr | p.H82Y | Q659C4 | protein_coding | deleterious(0.02) | possibly_damaging(0.521) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
LARP1B | deletion | Frame_Shift_Del | novel | c.501delN | p.Leu168Ter | p.L168* | Q659C4 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
LARP1B | SNV | Missense_Mutation | c.1988N>C | p.Gly663Ala | p.G663A | Q659C4 | protein_coding | deleterious(0.01) | benign(0) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
LARP1B | SNV | Missense_Mutation | rs201885302 | c.2146C>T | p.Arg716Cys | p.R716C | Q659C4 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1B | SNV | Missense_Mutation | novel | c.1172N>G | p.Ser391Cys | p.S391C | Q659C4 | protein_coding | deleterious(0.03) | benign(0.375) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LARP1B | SNV | Missense_Mutation | c.2129N>C | p.Gln710Pro | p.Q710P | Q659C4 | protein_coding | deleterious(0) | possibly_damaging(0.898) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
LARP1B | SNV | Missense_Mutation | c.1418G>T | p.Arg473Leu | p.R473L | Q659C4 | protein_coding | deleterious(0) | possibly_damaging(0.491) | TCGA-AA-3850-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
LARP1B | SNV | Missense_Mutation | rs187112542 | c.907C>T | p.Arg303Cys | p.R303C | Q659C4 | protein_coding | tolerated(0.09) | benign(0.006) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1B | SNV | Missense_Mutation | rs369019229 | c.1817N>A | p.Arg606Gln | p.R606Q | Q659C4 | protein_coding | deleterious(0.03) | benign(0.135) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
LARP1B | SNV | Missense_Mutation | rs767497573 | c.1397N>A | p.Arg466Gln | p.R466Q | Q659C4 | protein_coding | deleterious(0.02) | benign(0.048) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |